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Abstract
Background: The aim of this study was to develop site-specific antibodies as a tool to capture
Plasmodium falciparum-dihydrofolate reductase (Pf-DHFR) from blood samples from P. falciparum
infected individuals in order to detect, in a sandwich ELISA, structural alterations due to point
mutations in the gene coding for Pf-DHFR. Furthermore, we wanted to study the potential use of
homology models in general and of Pf-DHFR in particular in predicting antigenic malarial surface
epitopes.
Methods: A homology model of Pf-DHFR domain was employed to define an epitope for the
development of site-specific antibodies against Pf-DHFR. The homology model suggested an
exposed loop encompassing amino acid residues 64–100. A synthetic peptide of 37-mers whose
sequence corresponded to the sequence of amino acid residues 64–100 of Pf-DHFR was
synthesized and used to immunize mice for antibodies. Additionally, polyclonal antibodies
recognizing a recombinant DHFR enzyme were produced in rabbits.
Results and conclusions: Serum from mice immunized with the 37-mer showed strong reactivity
against both the immunizing peptide, recombinant DHFR and a preparation of crude antigen from
P. falciparum infected red blood cells. Five monoclonal antibodies were obtained, one of which
showed reactivity towards crude antigen prepared from P. falciparum infected red cells. Western
blot analysis revealed that both the polyclonal and monoclonal antibodies recognized Pf-DHFR.
Our study provides insight into the potential use of homology models in general and of Pf-DHFR
in particular in predicting antigenic malarial surface epitopes.
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Background
Antibodies raised against short peptide fragments of a
given protein have been reported to be able to cross-react
with the native protein [1]. The identification of peptide
epitopes simulating the native protein has traditionally
been based on amino acid sequences or sequence motifs
exposed on the outer surface of the protein structure,
thereby making these peptides potential candidates as
antigen epitopes. Examples of algorithms for selecting
and defining properties of exposed peptide sequences
include plots of hydrophilicity, hydrophobicity, external
flexibility and antigenic index. However, these algorithms
provide only crude approximations of the native struc-
tures, and antibodies raised against the selected peptides
are often lacking reactivity or show low degree of cross-
reactivity with the native protein [2]. In recent years, the
number of proteins for which three-dimensional struc-
tures have been determined by experimental and compu-
tational methods has increased dramatically [3]. The
information could aid in a more precise identification of
antigenic epitopes as opposed to defining epitopes based
solely on the primary sequence of the protein.
The objective of the present study was to exploit the three-
dimensional model of the Plasmodium falciparum dihydro-
folate reductase (Pf-DHFR) domain to define peptide
epitopes for the development of site-specific monoclonal
antibodies against Pf-DHFR. The Pf-DHFR is a target of
antifolatic drugs, i.e. pyrimethamine and cycloguanil.
Resistance to pyrimethamine is linked to point mutations
in the gene coding for Pf-DHFR [4-6].
The rationale for the development of site-specific antibod-
ies as opposed to antibodies targeting the more general Pf-
DHFR epitopes was a desire at later stage to develop sec-
ondary antibodies targeting specific epitopes on Pf-DHFR
linked to drug resistance. Such antibodies would enable
epidemiological studies of drug resistance in malaria. The
feasibility of epitope mapping employing the structural
model for Pf-DHFR was demonstrated by testing the reac-
tivity of mouse polyclonal and monoclonal antibodies
against native Pf-DHFR raised against a synthetic peptide
identified as an exposed loop-peptide from the model
structure. As a comparative experiment, rabbit polyclonal
antibodies raised against the recombinant P. falciparum
DHFR enzyme were used.
Materials and Methods
Computational analysis of Pf-DHFR
The homology model of Pf-DHFR was constructed based
on the reported DHFR crystal structures of vertebrates
(human and chicken), bacteria (Escherichia coli and Lacto-
bacillus casei) and fungi (Pneumocystis carinii) as templates
[7]. In these organisms, the DHFR and thymidylate syn-
thase (TS) exist as separate monofunctional enzymes
whereas the two enzymes in protozoa reside on the same
polypeptide as a bifunctional DHFR-TS protein. Until
recently, the only known three-dimensional structure of a
bifunctional DHFR-TS protein was from Leishmania major
[8]. Comparative analysis of the homology model of Pf-
DHFR and the structures of mono-functional enzymes
from other organisms revealed remarkable similarity with
respect to its overall topology, except for the presence of
two loop regions, a junctional peptide bridging the DHFR
and TS domains, and the N-terminal extension in the case
of L. major and P. falciparum DHFR-TS enzymes. Using
SYBYL molecular modelling system, version 6.3 (Tripos
Associates, St. Louis, MO, USA), the homology model of
Pf-DHFR domain was exploited for the analysis of epitope
candidates. Primary sequence analysis of Pf-DHFR was
performed using the Protean software, (Lasergene, DNA
Star software package, DNA Star Inc, Madison, Wl 53715,
USA).
Immunization of mice with selected peptide and 
production of monoclonal antibodies
Ten mg of peptide (a 37-mer peptide selected as described
in the results section with a purity of >95% as determined
by HPLC) was synthesized by K.J. Ross-Petersen (Hør-
sholm, Denmark). The peptide was coupled to purified
protein derivative of tuberculin (PPD) as a carrier at a
ratio of 5:1 in 0.2% glutaraldehyde and the reaction was
allowed to incubate overnight at 4°C. Five mice
(CF1XBalbC) were immunized by intraperitoneal injec-
tion with 0.5 ml of the peptide solution (0.05 mg/ml pep-
tide/PPD, 0.9% NaCI, 0.67 mg/ml AI(OH)3, 0.05%
merthiolate). After 2 weeks, the mice sera were tested for
reactivity to the peptide by ELISA: Briefly, the ELISA plate
was coated overnight at 4°C with 0.3 µg/ml peptide solu-
tion (in PBS). The plate was washed three times with
washing buffer (0.37 M NaCI, 1% Triton X-100 in PBS,
pH 7.4). Sera (1:10 dilution) in dilution buffer (washing
buffer containing 1% BSA) were added to the wells and
the reaction was allowed to incubate for 1 hour at room
temperature. The plate was washed three times with wash-
ing buffer and secondary horseradish peroxidase rabbit
anti-mouse-immunoglobulin-conjugated antibody
(P260, DAKO, Glostrup, Denmark) with dilution buffer
(1:1000) was added to each well. The plate was incubated
for 1 hour at room temperature, followed by three times
of washing with washing buffer. An o-phenylene-diamine
(OPD) solution containing 1.5 mg/ml of 1,2-phenyldi-
amine dihydrochloride (DAKO, Glostrup, Denmark) dis-
solved in water and 0.015% H2O2 was added and the plate
incubated at room temperature for 30 min. Adding 1 M
H2SO4 stopped the reaction and the optical density at 492
nm was measured by an ELISA reader.
Spleen cells from the highest responder mouse were fused
with myeloma cells (X63Ag8.6.5.3) according toMalaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/16
Page 3 of 7
(page number not for citation purposes)
procedures reviewed in [9]. The supernatant fractions
from the fusions were tested by ELISA as described above,
by incubating each supernatant in ELISA wells for 1 hour
at room temperature (1:10 in dilution buffer). The well
with the highest reactivity was selected and grown again
and the procedure was repeated until a high reactivity
from all wells with grown cells was obtained. The cell cul-
ture was now considered monoclonal allowing for mass-
culture production of monoclonal antibodies and purifi-
cation of antibodies.
Immunization of rabbits with recombinant DHFR and 
development of polyclonal antibodies
Recombinant DHFR (rDHFR) with a single point muta-
tion at A16V was prepared by others, as described [10]
and coupled to an immunogenic carrier-protein (S3,
secreted proteins from cultures of mycobacteria (BCG)) in
a molar ratio of 1:1. The complexed antigen was adsorbed
onto AI(OH)3 and emulsified with incomplete Freund's
adjuvant. The final vaccine contained 25 µg carrier-pro-
tein/mg AI(OH)3 and was given subcutaneously once,
four times with two weeks intervals in the back of rabbits.
The rabbit sera were tested by ELISA as described above for
the mice, but the resulting polyclonal antibodies were not
developed further into monoclonal antibodies.
Preparation of crude P. falciparum protein extract
The  P. falciparum culture isolate 3D7 was grown to
approximately 1.5 × 107 parasites/ml and the crude 3D7
protein extract enzyme was extracted according to [11].
The infected red blood cells were centrifuged at 2000 rpm
for 10 min. The pellet was washed twice in 10 ml PBS and
The molecular model of Pf-DHFR Figure 1
The molecular model of Pf-DHFR. The Pf-DHFR model (green) with the aa64-100 loop highlighted (red). The N-terminal 
part of the Pf-DHFR (white) was not included in the Pf-DHFR model and it is here shown together with the Leishmania major-
TS structure (white and cyan, respectively) to illustrative that the aa64-100 loop does not interfere with these parts of the 
DHFR-TS complex. The Pf-DHFR substrate and cofactor are just visible at the lower right part of Pf-DHFR (orange). The sur-
faces are solvent-accessible surfaces generated with SYBYL.Malaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/16
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centrifuged at 2000 rpm for 10 min. A freshly made
0.015% saponin solution in PBS (20 × pellet volume)
including one protease inhibitor cocktail tablet/10 ml
saponin solution was added to the pellet (Roche, Cat. No.
1836170). The solution was incubated at 37°C for 30
min. and vortexed once within this period and at the end.
The sample was subsequently kept on ice and centrifuged
at 5000 rpm for 10 min. at 4°C. The pellet was washed
twice in 10 ml of cold PBS. 3 ml of a 0.85% NaCI solution
was added and the solution was sonicated four times for
15 sec with 30 sec rest in between. Finally, the solution
was centrifuged at 15.000 rpm for 30 min. at 4°C and the
supernatant was either used immediately or frozen at -
20°C.
Dot blot analysis of mouse antiserum and of a monoclonal 
antibody tested against the loop-peptide and against an 
extract from infected red cells (crude 3D7 antigen)
The ability of mouse serum and monoclonal antibodies
raised against the synthetic aa64-100 peptide to recognize
the immunising peptide and crude 3D7 protein extract
was tested by dot blot analysis: The peptide and the 3D7
protein extract were pre-treated in various ways
(untreated, and combinations of boiling and incubation
with SDS, β-ME (β-mecapto-ethanol), and IAA (imidoace-
tic acid)) and subsequently 2.5 µl was dotted onto nitro-
cellulose paper strips (Hybond, RPN2020E, Amersham)
and allowed to dry. The strips were incubated in blocking
buffer (0.25 M Tris-base, 2.5 M NaCI, 0.5% Tween-20 in
H2O, ph: 7.6) for 15 min and incubated with mouse
serum or monoclonal antibody culture supernatant (1:5)
Dot blot analysis of mouse polyclonal and monoclonal antibodies raised against the aa64-100 peptide when tested against the  loop peptide and crude P. falciparum 3D7 protein extract in the presence of various reagents interfering with protein structure Figure 2
Dot blot analysis of mouse polyclonal and monoclonal antibodies raised against the aa64-100 peptide when 
tested against the loop peptide and crude P. falciparum 3D7 protein extract in the presence of various reagents 
interfering with protein structure. The reactivity to two-fold dilutions of crude 3D7 protein extract of polyclonal and 
monoclonal antibodies are shown. As a positive control the reactivity to the aa64-100 peptide solution (10 µg/ml, two-fold 
diluted) is shown. Crude 3D7 protein extract was pre-treated before dotting as indicated: 1: untreated, 2: boiled, 3: β-ME, 4: β-
ME + boiled, 5: β-ME + IAA, 6: β-ME + IAA + boiled, 7: 0.1 % SDS, 8: 0.1 % SDS + boiled, 9: 0.1 % SDS + β-ME, 10: 0.1 % SDS 
+ β-ME +boiled, 11: 0.1 % SDS + β-ME + IAA, 12: 0.1 % SDS + β-ME + IAA + boiled, B: Buffer control.
Mouse serum against 3D7 crude antigen Mouse serum against peptide aa64-100
MAb against 3D7 crude antigen MAb against peptide aa64-100
Mouse serum against 3D7 crude antigen Mouse serum against peptide aa64-100
MAb against 3D7 crude antigen MAb against peptide aa64-100Malaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/16
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in washing buffer (0.25 M Tris-base, 2.5 M NaCI, 0.05%
Tween-20 in water, pH: 7.6) over night at room tempera-
ture. The strips were washed twice in washing buffer for 2
× 10 min. Secondary goat anti mouse IgG conjugated to
horse radish peroxidase (CHEMICON International,
AP127P) was added (1:4000 in washing buffer) and incu-
bated for 1 hour at room temperature. The strips were
washed twice in washing buffer for 2 × 10 min. and then
incubated in developing solution (3-amino-9 ethyl caba-
zol, N,N'-dimethyle-formamide and colour buffer
(CH3COOH and NaOH, pH 5,0) for 15 min. at room
temperature protected from light. The strips were let to
dry.
Western blot
SDS-PAGE and Western blot was prepared to estimate the
size of the products recognized by the aa64-100 antibody
and the polyclonal antibody raised in rabbits. SDS-PAGE
was performed on gels consisting of 10 ml of separating
gel (8%), made by adding 2 ml acrylamide solution (40%
acylamide, 0.8% bis-acylamide), 2.5 ml separation buffer
with 0.1% SDS (1.5 M Tris-HCI (pH: 8.8)) and 5.5 ml
water with 100 µl 10% ammonium persulfate and 8 µl
TEMED. 10 ml stacking gel (5%) was made by adding
1.25 ml 40% acrylamide solution, 2.5 ml stacking buffer
with 0.1% SDS (1 M Tris-HCI (pH: 6.8)) and 6.25 ml H2O
with 100 µl 10% ammonium persulfate 8 µl TEMED. The
samples were diluted 1:1 in sample buffer (125 mM Tris-
HCI (pH: 6.8), 20% glycerol, 10% SDS, 0.01%
bromophenol blue, 40 mM DTT 1.4 ml water). Electro-
phoresis was performed for 1.5 hours at 160 V. The gel
was subsequently semi-dry blotted onto nitrocellulose
paper in blotting buffer (25 mM Tris-base, 20% ethanol in
H2O, pH: 10.4) for 1 hour at 200 mA. The nitrocellulose
membrane was incubated with blocking buffer (0.05 M
Tris-base, 0.5 M NaCI, 0.5% Tween-20 and 5% skimmed
milk in H2O, pH: 7.6) at room temperature for 15–30
min. The monoclonal antibodies were diluted 1:5 in
washing buffer (0.05 M Tris-base, 0.5 M NaCI, 0.05%
Tween-20 in H2O, pH: 7.6) and incubated overnight at
room temperature. The membrane was washed twice in
washing buffer and secondary antibody conjugated to
alkaline phosphatase (P314, DAKO, Glostrup, Denmark)
was added (1:1000 in washing buffer) and incubated for
1 hour at room temperature. The membrane was washed
and 50 ml of a NBT/BCIP (NBT: nitro blue tetrazoleum,
Sigma N-5515, BCIP: 5-bromo-4-chloro-3-indolyl-phos-
phate, Sigma B-0274) solution as recommended by the
manufacturers was added to the membrane and incubated
for 30 min. at room temperature and let to dry.
Results
The selection of a potential antigenic region
Using SYBYL molecular modelling system, the homology
model of Pf-DHFR domain was exploited for the analysis
of epitope candidates and a single potential antigenic
region was identified remotely located in respect to the
active site of the enzyme. The DHFR-TS and the chosen
structure forming a loop spanning aa64-100 is shown in
figure 1. Loops with certain length of amino acids are
often highly flexible and positioned externally, hence are
potentially antigenic. Although in the homology model
the exact structure of the loop spanning aa64-100 has not
been defined, the loop is predicted to locate externally
and the TS domain does not conceal it. Furthermore, it
does not interfere with the active sites of neither the DHFR
nor the TS part of the bifunctional enzyme. According to
the model aa64 (Tyr64) and aa100 (Asn100) are within
Van Der Waals contact to each other and exhibit a distance
between the C-alpha atoms of 6.0 Å. Thus, in order to
attempt to induce the same conformation in the synthetic
peptide, Tyr64 and Asn100 was replaced by Cys residues
so that the synthetic peptide could form disulphide bonds
and thereby presumed a loop structure similar to that pre-
dicted from the native Pf-DHFR protein. The validity of
the antigenic epitope was analysed by primary sequence
analysis of Pf-DHFR applying different algorithms (data
not shown). According to the generated plots and the
analyses of the stretch of amino acids spanning the resi-
dues 64–100, there were a few candidates selected that
met the criteria predicted and that were highly flexible.
However, the stretch of the epitope peptide would most
likely have consisted of a fraction of the aa64-100 section
if merely depending on these plots and the knowledge of
the proximity of the aa64 and aa100 would not have been
taken into account and considered as an important factor
in the design of the synthetic peptides.
Dot blot analysis of immune mouse sera and monoclonal 
antibodies
The ability of the mouse polyclonal and monoclonal anti-
bodies raised against the synthetic aa66-100 peptide to
recognize the loop peptide and crude 3D7 protein is
shown in figure 2. Of five monoclonal antibodies selected
for strong reactivity, only one recognized the 3D7 antigen
preparation (not shown), and this monoclonal antibody
was selected for further analysis.
In order to find out under which conditions the crude
3D7 is recognized by the mono- and polyclonal antibod-
ies (3D7 in its native form, denatured, reduced), the
extract was tested in a variety of environments, see figure
2. It appears that boiling the 3D7 extract for 5 min.
improved the reactivity of the monoclonal antibody,
whereas treatment of the extract with 0,1% SDS inhibited
the binding.
The polyclonal antibody raised against the synthetic pep-
tide shows reactivity to the crude extract under all condi-
tions except when the antigen was treated with β-ME +Malaria Journal 2004, 3 http://www.malariajournal.com/content/3/1/16
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IAA. The recognition of the untreated 3D7 crude antigen
by the polyclonal antibodies indicates that the immune
mouse serum contains antibodies against native Pf-DHFR
from 3D7 crude extract.
Size estimation of the recognized product by Western blot
A Western blot analysis after separation of 3D7 proteins
on an SDS-PAGE gel was performed in order to estimate
the size of the product recognized by the monoclonal
aa64-100 antibody selected for reactivity to 3D7 antigen
and the polyclonal antibody to rDHFR raised in rabbits.
As shown in figure 3, the Western blot revealed that both
the aa64-100 monoclonal antibody and the polyclonal
rDHFR antibody recognized one major product of
approximately 70 kD.
Discussion
The objective of the present study was to analyse the fea-
sibility of defining potential antigenic epitopes of a pro-
tein, P. falciparum DHFR (Pf-DHFR), by exploring a three-
dimensional structure obtained by homology building
from the known structure of DHFR from other species
(vertebrates, bacteria, fungi). An epitope was selected
based on its exposed loop-structure and potential flexibil-
ity and mice were immunized with a synthetic 37-mer
peptide. Additionally, a polyclonal antibody towards
recombinant DHFR enzyme (rDHFR) was raised in rab-
bits. Polyclonal antisera from the immunized mice
showed strong reactivity with the peptide, with rDHFR,
and with a preparation of crude antigen from P. falciparum
infected red blood cells. Five monoclonal antibodies were
developed with high reactivity to the peptide, however
only one of these cross-reacted strongly with crude P. fal-
ciparum protein extract when tested by dot blot and was
further analysed. The western blot showed that the aa64-
100 antibody, as well as the polyclonal antibody towards
rDHFR recognized one major product of approximately
70 kD, most likely to be Pf-DHFR. (including thymidylate
synthetase, TS). The predicted molecular weight of Pf-
DHFR-TS is 71.8 kD. The fact that the aa64-100 antibody
reacted strongest after boiling of the crude extract and
showed low reactivity to the untreated extract indicates
that this monoclonal antibody has relatively low affinity
to DHFR in its native state. However, the test (figure 2) of
mouse serum immunized with the synthetic loop peptide
aa64-100 leads us to the conclusion that it is possible to
raise antibodies with high affinity to the DHFR in its
native state.
Apart from the aa64-100 antibody, the other loop target-
ing monoclonal antibodies may have been directed
against more extended conformations of the aa64-100
fragment. Despite the substitutions at aa64 and aa100
with cysteine, allowing the formation of a disulphide
bond, only a small fraction of the peptide population may
eventually form the intended loop structure. The aa64-
100 fragment has a cysteine at aa78 and alternative disul-
phide bonds may have been formed of the aa64-100 pep-
tide than the one intended. Furthermore, as a result of the
high flexibility of loops in general, only a minor fraction
of the formed peptide loops may actually resemble the
native aa64-100 loop at any given time point, potentially
leading to low immunization efficacy and/or low ELISA
sensitivity towards the native protein. After completion of
the biochemical studies the three-dimensional structure
of the bifunctional Pf-DHFR-TS protein was determined
by X-ray crystallography [12]. This provides a unique
Western blots of crude P. falciparum 3D7 protein extract  reacted with aa64-100-monoclonal antibody and rabbit poly- clonal antibody Figure 3
Western blots of crude P. falciparum 3D7 protein 
extract reacted with aa64-100-monoclonal antibody 
and rabbit polyclonal antibody. (M) Pre-stained protein 
marker, (1) aa64-100 (10 µg/ml) of the purified antibody; (2) 
1:50 dilution of rabbit-antibody. In each lane approximately 
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opportunity to see if the structural basis for the selection
of the aa64-100 epitope was correct. In the experimental
structure aa66-81 is forming an α-helix whereas aa86-95
cannot be located. In the model no secondary structure
can be identified in the aa64-100 loop. Thus, although
there are structural differences between the experimental
structure and the model the similarities are also striking.
In the experimental structure the distance between the
Tyr64 and Asn100 C-alpha atoms is 7.5 Å compared with
6.0 Å in the model. Thus, the aa64-100 loop is anchored
similarly and in both the experimental structure and the
model this part of the Pf-DHFR is located on the surface
and accordingly accessible for interactions with
antibodies.
The three-dimensional structure analysis provided
detailed knowledge of precise positions of surface
exposed structures, enabling the development of site-
directed antibodies that could not have been predicted by
the primary structure analysis alone. This approach may
therefore contribute significantly to the likelihood of
selecting valuable peptide epitopes and whenever possi-
ble, epitope mapping by the primary sequence plots
should be compared to the three-dimensional structures.
Authors' contributions
MA, AMR, ICB and CK designed and supervised the over-
all study. ITC and FSJ did the modelling, JEW, MC and YP
contributed with various laboratory techniques, WS sup-
plied the recombinant DHFR.
Acknowledgements
We are most grateful to the excellent technical assistance of Bettina Holm 
and Annette Schioldborg in performing different ELISA tests. We appreci-
ate Trine Staalsoe and laboratory technicians Anne Corfitz and Kirsten Pihl 
for P. falciparum 3D7 culture.
The study received financial support from Danish International Develop-
ment Agency (DANIDA) Research Council (RUF, Grant no. 90892).
References
1. Dyson HJ, Wright PE: Antigenic peptides. FASEB 1995, 9:37-42.
2. Van Regenmortel MH, Pellequer JL: Predicting antigenic determi-
nants in proteins: looking for unidimensional solutions to a
three-dimensional problem? Pept Res 1994, 7:224-228.
3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H,
Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids
Res 2000, 28:235-242.
4. Peterson DS, Walliker D, Wellems TE: Evidence that a point
mutation in dihydrofolate reductase-thymidylate synthase
confers resistance to pyrimethamine in falciparum malaria.
Proc Natl Acad Sci U S A 1988, 85:9114-9118.
5. Foote SJ, Galatis D, Cowman A: Amino acids in the dihydrofolate
reductase-thymidylate synthase gene of Plasmodium falci-
parum involved in cycloguanil resistance differ from those
involved in pyrimethamine resistance. Proc Natl Acad Sci USA
1990, 87:3014-3017.
6. Peterson DS, Milhous WK, Wellems TE: Molecular basis of differ-
ential resistance to cycloguanil and pyrimethamine in Plas-
modium falciparum malaria.  Proc Natl Acad Sci U S A 1990,
87:3018-3022.
7. Lemcke T, Christensen IT, Jorgensen FS: Towards an understand-
ing of drug resistance in malaria: three-dimensional struc-
ture of Plasmodium falciparum dihydrofolate reductase by
homology building. Bioorg Med Chem 1999, 7:1003-1011.
8. Knighton DR, Kan CC, Howland E, Janson CA, Hostomska Z, Welsh
KM, Matthews DA: Structure of and kinetic channelling in
bifunctional dihydrofolate reductase-thymidylate synthase.
Nat Struct Biol 1994, 1:186-194.
9. Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K,
Murray PG: Monoclonal antibodies. Mol Pathol 2000, 53:111-117.
10. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV:
Antifolate-resistant mutants of Plasmodium falciparum dihy-
drofolate reductase. Proc Natl Acad Sci USA 1997, 94:1124-1129.
11. Inselburg J, Zhang RD: Study of dihydrofolate reductase-thymi-
dylate synthase in Plasmodium falciparum. Am J Trop Med Hyg
1988, 39:328-336.
12. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul
J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y: Insights
into antifolate resistance f r o m  m a l a r i a l  D H F R - T S
structures. Nat Struct Biol 2003, 10:357-365.